邁博藥業(02181.HK)治療直腸癌核心產品上市註冊申請獲受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

邁博藥業(02181.HK)治療直腸癌核心產品上市註冊申請獲受理

阿思達克 03-15 00:52

邁博藥業－Ｂ(02181.HK)公布，公司核心產品之一CMAB009的上市註冊申請近日獲中國國家藥監局受理，用於治療轉移性結直腸癌。 CMAB009為一種重組抗表皮生長因子受體嵌合單克隆抗體，是首個向國家藥監局申請NDA的用於結直腸癌治療的中國國產抗EGFR單克隆抗體藥物。

邁博藥業-B(02181.HK)

Relevant Stocks

邁博藥業-B(02181.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

邁博藥業(02181.HK)治療直腸癌核心產品上市註冊申請獲受理

Services

About Us

Agreement Statement